18 Aug 2026 Recon: FDA releases draft guidance on gen AI-enabled devices; Industry warns Germany must reform drug pricing Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
17 Aug 2026 Recon: FDA approves Zenbexus for multiple myeloma; NSAI seeks buyer for its MDR notified body business Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
13 Aug 2026 Recon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in China Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
11 Aug 2026 Recon: FDA rejects ITM radiopharma therapy; WHO defends immunization schedules Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
10 Aug 2026 Recon: BMS plans $2.3B Houston manufacturing site; MHRA approves Lilly weight-loss drug for weight loss, type 2 diabetes Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
06 Aug 2026 Recon: FDA approves first drug for type 1 narcolepsy, mRNA flu vaccine; No merger talks between AstraZeneca-BMS Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
04 Aug 2026 Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
03 Aug 2026 Recon: AstraZeneca, BMS discuss merger; FDA broadens indication for Novartis’ Pluvicto Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
30 Jul 2026 Recon: FDA adcomm votes against Capricor’s DMD drug; Cytokinetics gets UK approval, NICE backing for heart drug Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
27 Jul 2026 Recon: WHO releases first interim list of medical device authorities; AstraZeneca using AI to hedge late-stage risks Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
